The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) last traded at $39.71, down -7.67% from the previous session.
SRPT stock price is now -18.59% away from the 50-day moving average and -60.54% away from the 200-day moving average. The market capitalization of the company currently stands at $3.90B.
On May 08, 2025, Evercore ISI Downgraded its previous ‘Outperform’ rating to ‘In-line’ on the stock keeping its target price maintained at $50, while ‘Wells Fargo’ rates the stock as ‘Overweight’
In other news, Nicaise Claude, Director sold 2,491 shares of the company’s stock on Mar 12 ’25. The stock was sold for $248,203 at an average price of $99.64. Upon completion of the transaction, the Director now directly owns 27,812 shares in the company, valued at $1.1 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 12 ’25, Director Nicaise Claude bought 2,491 shares of the business’s stock. A total of $248,226 was incurred on buying the stock at an average price of $99.65. A total of 4.99% of the company’s stock is owned by insiders.
During the past 12 months, Sarepta Therapeutics Inc has had a low of $34.10 and a high of $173.25. As of last week, the company has a debt-to-equity ratio of 1.18, a current ratio of 4.02, and a quick ratio of 2.46.
The net profit margin was -11.12% and return on equity was -23.61% for SRPT. The company reported revenue of $744.86 million for the quarter, compared to $413.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 80.15 percent.
